A Study of TQB3454 Tablets in Patients With Blood Tumors
NCT06218771 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2024-01-23
Summary
The purpose of this clinical trial is to evaluate the safety of TQB3454 tablets in patients with acute myeloid leukemia and myelodysplastic syndrome, and determine the phase II recommended dose.
Conditions
Interventions
- DRUG
-
TQB3454 Tablets
TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
Sponsors & Collaborators
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-10
- Primary Completion
- 2025-06-30
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
NCT06049667 ·Status: RECRUITING ·Phase: PHASE1
-
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT05445154 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
NCT01751867 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome
NCT02013102 ·Status: UNKNOWN ·Phase: PHASE4
-
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00015834 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
NCT04925141 ·Status: COMPLETED ·Phase: PHASE4
-
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
NCT00101816 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT05241093 ·Status: RECRUITING ·Phase: PHASE2
-
To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS
NCT05740917 ·Status: UNKNOWN ·Phase: PHASE1
-
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
NCT00459212 ·Status: COMPLETED ·Phase: PHASE1
-
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00255346 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT05241106 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT01363817 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT01795924 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT03671564 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04443751 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
NCT05944978 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT05518357 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
NCT01177540 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
NCT01201811 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
NCT00405054 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
NCT05424380 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NCT02859948 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
NCT02954653 ·Status: TERMINATED ·Phase: PHASE1